Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015
Cited by 970 works. doi:10.1016/s0140-6736(15)01238-6
Authors
- Gérard Zalcman
- Julien Mazières
- J. Margery
- Laurent Greillier
- Clarisse Audigier-Valette
- Denis Moro‐Sibilot
- Olivier Molinier
- R. Corre
- I. Monnet
- Valérie Gounant
- F. Rivière
- Henri Janicot
- R. Gervais
- Chrystèle Locher
- Bernard J. Milleron
- Marie-Paule Lebitasy
- Franck Morin
- Christian Créveuil
- Jean‐Jacques Parienti
References
- A Multiple Testing Procedure for Clinical Trials
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Interpreting the significance of changes in health-related quality-of-life scores.
- Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
- Randomized trials stopped early for benefit: a systematic review.
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- Multiple testing in clinical trials
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma